Clinical trial
A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically…
NCT00287079 · Merck KGaA, Darmstadt, Germany, Industry · Completed
Key facts
| NCT number | NCT00287079 |
|---|---|
| Title | A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome |
| Official title | A Prospective, Open Label, Multi-centre Study Exploring the Use of Subcutaneous (sc) 44 Microgram Interferon (IFN) Beta - 1a (Rebif®) Once a Week (qw) in Subjects With Clinically Isolated Syndrome (CIS) |
| Acronym | CIS-ON |
| Lead sponsor | Merck KGaA, Darmstadt, Germany, Industry |
| Collaborators | EMD Serono Canada Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Clinically Isolated Syndrome |
| Intervention type | Drug, Other |
| Interventions | Rebif®, No Treatment |
| Enrollment | 35 |
| Start date | Oct 1, 2005 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Feb 6, 2006 |
| Last update posted | Dec 27, 2013 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: